ArticleLupus science & medicine2026
Increasing the utilisation of hydroxychloroquine blood level testing in lupus: a quality improvement project.
Article in Lupus science & medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveHydroxychloroquine (HCQ) is a cornerstone therapy for SLE, reducing flares, organ damage and mortality. However, weight-based dosing yields highly variable drug exposure, which can result in suboptimal treatment. Measuring HCQ blood levels provides an objective tool to assess adherence and guide individualised dosing. Although available at our academic medical centre, this testing remains infrequently ordered in routine practice. We aimed to increase HCQ testing in patients with SLE through a structured quality improvement initiative and to characterise the clinical distribution of HCQ level results among tested patients.
methodsWe conducted a single-centre quality improvement project from August 2024 to November 2025 using a Plan-Do-Study-Act framework. Interventions included multidisciplinary education, development of institutional guidelines and implementation of an order set incorporating HCQ testing at prescribing. The primary outcome was the proportion of eligible patients with SLE with HCQ testing. As a secondary analysis, HCQ level results were categorised into four clinically meaningful ranges (severe non-adherence, subtherapeutic, therapeutic and supratherapeutic) based on published literature.
resultsAmong nearly 1000 adult patients with SLE, HCQ testing increased from 4% to 15% (absolute increase of 11 percentage points; more than threefold relative). Provider adoption increased from 24% (8/33) to 73% (24/33) of rheumatologists. Among 170 tested patients, 79.4% had HCQ levels below the therapeutic range, including 14.7% with severe non-adherence (<200 ng/mL), approximately twice that in published cohorts.
conclusionsThis real-world quality improvement initiative demonstrates both the feasibility and clinical yield of integrating HCQ monitoring into routine SLE care. Beyond increasing test utilisation, monitoring revealed a substantial burden of HCQ exposure below the therapeutic range that would have remained invisible without systematic testing. The model is readily adaptable to other centres, particularly those serving populations facing access barriers.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.